Diphenoxylate Hydrochloride

CHEMBL1200665 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

489.0 g/mol

LogP

—

Phase

4

The hydrochloride salt form of diphenoxylate, used in combination with atropine in oral liquid and tablet formulations for diarrhea treatment. It slows gut motility via opioid receptors in the intestinal wall. The small amount of atropine present discourages misuse.

Masse moléculaire

489,0000 g/mol

TPSA

53,30 Å²

Aires thérapeutiques

Ovarian Cancer Non-Small Cell Lung Cancer Lymphoma Breast Cancer

Mécanisme d'action

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1.Cl

InChI

InChI=1S/C30H32N2O2.ClH/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27;/h3-17H,2,18-23H2,1H3;1H

Molecular Formula

C30H33ClN2O2

HBD / HBA

1 / 4

Liaisons Rotatives

9

Atomes Lourds

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

The hydrochloride salt form of diphenoxylate, used in combination with atropine in oral liquid and tablet formulations for diarrhea treatment. It slows gut motility via opioid receptors in the intestinal wall. The small amount of atropine present discourages misuse.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Diphenoxylate Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200665. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6432394. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Diphenoxylate Hydrochloride sur PillFYI

Structure

Données Clés

Formule: C30H33ClN2O2
Synonymes: 2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.